drugset / Trial / NCT01188421
Medications Development for Drug Abuse Disorders
Phase 1/2
Completed
106 enrolled
Johns Hopkins University
National Institute on Drug Abuse (NIDA) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a study of tramadol as an agent for short-term opioid withdrawal treatment. A randomized, double blind clinical trial comparing the efficacy and safety of tramadol to clonidine and buprenorphine in the short-term treatment of opioid withdrawal will be conducted. Opioid dependent participants will be treated on a residential unit. The primary outcome measure is opioid withdrawal symptoms.
Timeline
- Start
- 2010-10
- Primary completion
- 2015-06
- Completion
- 2015-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Buprenorphine | Other / unclassified | 8 mg | Other |
| Comparator | Clonidine | Other / unclassified | 0.8 mg | Oral |
| Comparator | Naloxone | Small molecule | 2 mg | Other |
| Subject | Tramadol | Other / unclassified | 600 mg | — |